Journal Article

Genetic alterations and their clinical implications in older patients with acute myeloid leukemia

Tsai, C-H, Chen, C-Y, Chiang, Y-C, Ko, B-S, Liu, C-Y, Li, C-C, Liu, C-W, Lin, C-C, Tseng, M-H, Hsu, S-C, Hou, H-A, Huang, S-Y, Chou, W-C, Tien, H-F, Kuo, Y-Y, Lin, L-I, Tsay, W, Yao, M, Tang, J-L, Liu, M-C, Lin, C-T, Wu, S-J

2016

Overview

A number of patient-specific and leukemia-associated factors are related to the poor outcome in older patients with acute myeloid leukemia (AML). However, comprehensive studies regarding the impact of genetic alterations in this group of patients are limited. In this study, we compared relevant mutations in 21 genes between AML patients aged 60 years or older and those younger and exposed their prognostic implications. Compared with the younger patients, the elderly had significantly higher incidences of PTPN11 , NPM1 , RUNX1 , ASXL1 , TET2 , DNMT3A and TP53 mutations but a lower frequency of WT1 mutations. The older patients more frequently harbored one or more adverse genetic alterations. Multivariate analysis showed that DNMT3A and TP53 mutations were independent poor prognostic factors among the elderly, while NPM1 mutation in the absence of FLT3 /ITD was an independent favorable prognostic factor. Furthermore, the status of mutations could well stratify older patients with intermediate-risk cytogenetics into three risk groups. In conclusion, older AML patients showed distinct genetic alterations from the younger group. Integration of cytogenetics and molecular mutations can better risk-stratify older AML patients. Development of novel therapies is needed to improve the outcome of older patients with poor prognosis under current treatment modalities.

• Publisher: Nature Publishing Group UK,Nature Publishing Group
• Subject: 45/22 / 45/23 / 45/41 / 45/77 / 631/1647/2217/457/649 / 631/208/68 / 631/67/1990/283/1897 / 692/699/1541/1990/283/1897 / 692/700/1518 / Acute myeloid leukemia / Age Factors / Aged / Aged patients / Aged, 80 and over / Cancer / Cancer Research / Chemotherapy / Clinical outcomes / Critical Care Medicine / Cytogenetics / DNA (Cytosine-5-)-Methyltransferases - genetics / Drug dosages / Female / fms-Like Tyrosine Kinase 3 - genetics / Gene mutations / Genes / Genes, p53 - genetics / Genetic analysis / Genetic aspects / Health aspects / Hematology / Hospitals / Humans / Intensive / Internal Medicine / Laboratories / Leukemia / Leukemia, Myeloid, Acute - diagnosis / Leukemia, Myeloid, Acute - genetics / Male / Medical prognosis / Medicine / Medicine & Public Health / Methods / Middle Aged / Multivariate Analysis / Mutation / Nuclear Proteins - genetics / Older people / Oncology / original-article / p53 Protein / Patient outcomes / Patients / Prognosis / Risk / Risk Assessment / Risk groups / Runx1 protein